After receiving pembrolizumab monotherapy, TP53 WT patients showed the optimal response, while patients with TP53 C-LOH barely responded to ICI, suggesting that in future clinical practice, it may be possible to precisely stage GC patients based on TP53 mutation status. The gene discussed is TP53; the disease is gastric cancer.